Data to be presented at the Society of Critical Care Medicine’s 47th Annual Critical Care Congress

NEWTON, Mass., Feb. 27, 2018 — Cheetah Medical, a Massachusetts-based leader in non-invasive fluid management devices, today announced the first presentation of major economic data showing total cost savings of over $1.4 million during a 6-month study in severe sepsis and septic shock patients. The data show that stroke volume optimization, guided by Cheetah technology, led to a reduction in ICU length of stay, and reduced the risk of both mechanical ventilation and initiation of acute dialysis.

Data from the same study, led by researchers from the University of Kansas Health System were previously published in the Journal of Critical Care and were presented at the International Symposium on Intensive Care and Emergency Medicine (ISICEM) Congress in Brussels last year.

Study results show significant clinical and economic benefits:

  1. ICU length of stay was reduced by 2.89 days, saving $8,953 per treated patient
  2. Risk of mechanical ventilation was reduced by 51 percent, saving $1,940 per treated patient
  3. Risk of acute dialysis initiation was reduced by 32 percent, saving $3,605 per treated patient

Together, the improvement in these three sepsis treatment components translated to substantial economic savings totalling $14,498 per patient treated, and $1,449,800 savings for the 6-month study duration.

Sepsis is a common and expensive condition to treat, costing $25,000 – $50,000 per patient, per episode.[i] Proper fluid management is vital to sepsis patients, as studies show that fluid overload is associated with an increase in mortality.[ii] As demonstrated with these data, a fluid resuscitation strategy in severe sepsis and septic shock patients, guided by stroke volume optimization with the Cheetah technology, may lead to a significant reduction in costs per episode.

“The economic benefits stemming from this six-month study serve as a reminder of how simultaneously dangerous and costly improperly managed IV fluids can be. This study highlights the opportunity for intensivists to enact more effective treatment plans for their septic patients and simultaneously benefit the hospital by reducing costs,” said Dr. Steven Q. Simpson, Interim Director of the Division of Pulmonary and Critical Care Medicine at the University of Kansas and a co-author of the study.

The results of this study echo Cheetah Medical’s focus as a company—helping critical care settings provide effective fluid management care to patients as well as reducing the economic burden associated with sepsis treatment.

“These data confirm that Cheetah’s technology can not only improve patient outcomes, but also save hospitals millions of dollars by helping clinicians guide fluid therapy to the unique needs of each patient,” said Chris Hutchison, president and CEO of Cheetah Medical. “We’re encouraged by the continued growth of our business and are excited to make incredible savings like this possible for hospitals around the world.”

Dr. Latham will be presenting these data, abstract #1451, on February 27 at 9:00 a.m. at the Society of Critical Care Medicine’s 47th Annual Critical Care Congress in San Antonio, Texas.

Details about the Cheetah Starling SV monitoring technology can be found at

About Sepsis

Sepsis is the body’s dangerous and over-reactive response to an infection. Instead of fighting off the infection, the body begins attacking itself, which can lead to tissue damage, organ failure and death. The condition was listed as the most expensive in-patient hospital cost in the U.S. in 2014, reaching almost $24 billion each year.[iii] Sepsis also accounts for 12.2 percent of hospital readmissions, compared to other conditions like heart failure (6.7 percent), pneumonia (5 percent) and heart attacks (1.3 percent).[iv] While there is no cure for sepsis, early detection and treatment with the proper amount of IV fluids and antibiotics can improve patient outcomes.[v]

About Cheetah Medical

Cheetah Medical is the pioneer and leading global provider of 100 percent non-invasive fluid management monitoring technologies, designed for use in critical care, operating room and emergency department settings. The Starling SV is fast becoming the gold standard in fluid management, as it provides immediate, dynamic assessments of fluid responsiveness, enabling clinicians to make more confident and informed treatment decisions regarding the proper amount of fluid required to maintain adequate organ and tissue perfusion. The company’s fluid management systems currently make an impact in more than 400 hospitals throughout the U.S. and in 25+ countries.

[i] Martin GS. Sepsis, severe sepsis and septic shock: changes in incidence, pathogens and outcomes. Expert Rev Anti Infect Ther 2012; 10(6) 701-706.

[ii] Kelm D et al. Fluid overload in patients with severe sepsis and septic shock treated with early goal directed therapy is associated with increased acute need for fluid-related medical interventions and hospital death. Shock 2015; 43:680-73.